Locations:
Search IconSearch
March 17, 2022/Cancer/Radiation Oncology

Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

21-CNR-2572058-CQD-Hero-650×450-1

A 61-year-old woman with a history of breast cancer was seen by a local oncologist after developing irregular purplish lesions on her chest. The patient underwent a biopsy, which revealed angiosarcoma – a finding associated with the radiation treatment she received during her previous breast cancer diagnosis 7 years earlier. Given the complexity of her disease and required treatment, she was referred to Cleveland Clinic for evaluation.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Unique treatment concerns

“This case was complicated for a number of reasons,” explains Chirag Shah, MD, a radiation oncologist in Taussig Cancer Institute and Director of Clinical Research in the Department of Radiation Oncology. “Angiosarcoma is a relatively rare and aggressive malignancy, so successful treatment demands a high level of expertise in several disciplines. If not treated early, the lesions can spread locally and/or metastasize rapidly and lead to a host of serious complications, including bleeding in the breast.”

The management of angiosarcoma can be especially challenging because the process may involve chemotherapy, repeat radiation, surgical resection, and even tissue reconstruction.

“In particular, many clinicians are uncomfortable treating the breast with repeat radiation, which is why cases like this one often get referred to large cancer centers for evaluation,” he says. “These cases can also be tricky because the best therapeutic approach is completely dependent on the specifics of each patient. There’s no one-size-fits-all solution.”

A CT scan taken during the radiation-planning phase
A CT scan taken during the radiation-planning phase reveals the tumor and associated skin thickening.

Novel, aggressive therapeutic approach

At Cleveland Clinic, the patient underwent a staging assessment and was evaluated by a multidisciplinary team of specialists, including medical oncologists, radiation oncologists, and surgeons. Concerned about the cancer’s rapid growth, the medical team began with a course of outpatient radiation therapy (60 Gy) three times daily for 4 weeks. The daily treatments were administered 4 hours apart.

“It is exquisitely uncommon for a patient to receive radiation multiple times a day over the course of several weeks,” explains Dr. Shah. “A treatment regimen like this demands a battery of technical considerations and significant staffing resources. It’s an exhausting, potentially painful course of therapy, so these patients really rely on their caregivers and support services to see them through. Toward the end of her treatment, this patient required almost daily wound care – a serious concern that required substantial nursing support.”

Advertisement

The patient underwent surgical removal of the affected breast eight weeks after she received her final radiation dose. Clinicians hoped the time frame would give the patient’s normal tissues time to repair. Only a small area of residual cancer was seen during the surgery.

“Angiosarcoma is like a weed – you can see the top of it, but it’s very difficult to gauge the depth of the root,” notes Dr. Shah. “In such cases, we often use wide margins when resecting the cancer to make sure we get it all.”

Long-term surveillance

The patient was closely monitored with physical exams and CAT scans of the chest; she was seen every 3 months for the first year and every 6 months for the second year. At her last follow-up appointment in 2021 (2 years post-treatment), she was disease-free.

“Most patients who require radiation of the breast breeze through the treatment, but this case was far riskier and more demanding,” concludes Dr. Shah. “The success of this case really comes down to the personalized, coordinated care the patient received. We were with her every step of the way.”

Advertisement

Related Articles

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Ad